Mark A. Nelson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mark A. Nelson has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
Aubin Moutal
Coll Pharm, Tucson, AZ 85721 USA
4 shared publicationsRajesh Khanna
Coll Pharm, Tucson, AZ 85721 USA
4 shared publicationsUdaiyappan Janakiraman
Univ Arizona, Coll Med, Dept Pathol, Tucson, AZ 85721 USA
4 shared publicationsChinnasamy Dhanalakshmi
Univ Arizona, Coll Med, Dept Pathol, Tucson, AZ 85721 USA
3 shared publicationsKohji Fukunaga
Tohoku Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, Sendai, Japan
3 shared publications- Aubin Moutal
Department of Pharmacology and Physiology, Saint Louis University School of Medicine, Saint Louis, Missouri, USA
2 shared publications
Latest Publications
- Open Access
- 22 February 2022
- Published by Springer Nature in Clinical Epigenetics
- Vol. 14 (1) , 1-6
Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease
We tested the ability of a novel DNA methylation biomarker set to distinguish metastatic pancreatic cancer cases from benign pancreatic cyst patients and to monitor tumor dynamics using quantitative DNA methylation analysis of cell-free DNA (cfDNA) from blood samples. The biomarkers were able to distinguish malignant cases from benign disease with high sensitivity and specificity (AUC = 0.999). Furthermore, the biomarkers detected a consistent decline in tumor-derived cfDNA in samples from patients undergoing chemotherapy. The study indicates that our liquid biopsy assay could be useful for management of pancreatic cancer patients.
- 22 February 2022
- Published by Springer Nature in Clinical Epigenetics
- Vol. 14 (1) , 1-6
Open AccessLiquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease
We tested the ability of a novel DNA methylation biomarker set to distinguish metastatic pancreatic cancer cases from benign pancreatic cyst patients and to monitor tumor dynamics using quantitative DNA methylation analysis of cell-free DNA (cfDNA) from blood samples. The biomarkers were able to distinguish malignant cases from benign disease with high sensitivity and specificity (AUC = 0.999). Furthermore, the biomarkers detected a consistent decline in tumor-derived cfDNA in samples from patients undergoing chemotherapy. The study indicates that our liquid biopsy assay could be useful for management of pancreatic cancer patients.
- Open Access
- 1 February 2021
- Published by Elsevier in Neurobiology of Disease
- Vol. 149, 105224
Evaluation of the effects of the T-type calcium channel enhancer SAK3 in a rat model of TAF1 deficiency
- 1 February 2021
- Published by Elsevier in Neurobiology of Disease
- Vol. 149, 105224
Open AccessEvaluation of the effects of the T-type calcium channel enhancer SAK3 in a rat model of TAF1 deficiency
- Open Access
- 1 September 2020
- Published by Elsevier in Neurobiology of Disease
- Vol. 143, 105006
The investigation of the T-type calcium channel enhancer SAK3 in an animal model of TAF1 intellectual disability syndrome
- 1 September 2020
- Published by Elsevier in Neurobiology of Disease
- Vol. 143, 105006
Open AccessThe investigation of the T-type calcium channel enhancer SAK3 in an animal model of TAF1 intellectual disability syndrome
- Open Access
- 1 December 2019
- Published by Elsevier in Neurobiology of Disease
- Vol. 132, 104539
TAF1-gene editing alters the morphology and function of the cerebellum and cerebral cortex
- 1 December 2019
- Published by Elsevier in Neurobiology of Disease
- Vol. 132, 104539
Open AccessTAF1-gene editing alters the morphology and function of the cerebellum and cerebral cortex
- Open Access
- 9 February 2019
- Published by Cold Spring Harbor Laboratory in bioRxiv
- p. 545491
TAF1-gene editing impairs Purkinje cell morphology and function
TAF1 intellectual disability syndrome is an X-linked disorder caused by loss-of-function mutations in the TAF1 gene. How these mutations cause dysmorphology, hypotonia, intellectual and motor defects is unknown. Mouse models which have embryonically targeted TAF1 have failed, possibly due to TAF1 being essential for viability, preferentially expressed in early brain development, and intolerant of mutation. Novel animal models are valuable tools for understanding neuronal pathology. Here, we report the development and characterization of a novel animal model for TAF1 ID syndrome in which theTAF1gene is deleted in embryonic rats using clustered regularly interspaced short palindromic repeats (CRISPR) associated protein 9 (Cas9) technology and somatic brain transgenesis mediated by lentiviral transduction. Rat pups, post-natal day 3, were subjected to intracerebroventricular (ICV) injection of either gRNA-control or gRNA-TAF1 vectors. Rats were subjected to a battery of behavioral tests followed by histopathological analyses of brains at post-natal day 14 and day 35.TAF1-edited rats exhibited behavioral deficits at both the neonatal and juvenile stages of development. Deletion of TAF1 lead to a hypoplasia and loss of the Purkinje cells. Abnormal motor symptoms in TAF1-edited rats were associated with irregular cerebellar output caused by changes in the intrinsic activity of the Purkinje cells. Immunostaining revealed a reduction in the expression of the CaV3.1 T-type calcium channel. This animal model provides a powerful new tool for studies of neuronal dysfunction in conditions associated with TAF1 abnormalities and should prove useful for developing therapeutic strategies to treat TAF1 ID syndrome.Significance Statement: Intellectual disability (ID) syndrome is an X-linked rare disorder caused by loss-of-function mutations in theTAF1gene. There is no animal model for understanding neuronal pathology and to facilitate development of new therapeutics for this X-linked intellectual disability syndrome. Novel animal models are valuable tools for understanding neuronal pathology and to facilitate development of new therapeutics for diseases. Here we developed a novel animal model for TAF1 ID syndrome in which theTAF1gene is deleted by CRISPR-Cas9 editing and lentiviral transduction. This animal model provides a powerful new tool for studies of neuronal dysfunction associated with TAF1 abnormalities and should prove useful for developing therapeutic strategies to treat TAF1 ID syndrome.
- 9 February 2019
- Published by Cold Spring Harbor Laboratory in bioRxiv
- p. 545491
Open AccessTAF1-gene editing impairs Purkinje cell morphology and function
TAF1 intellectual disability syndrome is an X-linked disorder caused by loss-of-function mutations in the TAF1 gene. How these mutations cause dysmorphology, hypotonia, intellectual and motor defects is unknown. Mouse models which have embryonically targeted TAF1 have failed, possibly due to TAF1 being essential for viability, preferentially expressed in early brain development, and intolerant of mutation. Novel animal models are valuable tools for understanding neuronal pathology. Here, we report the development and characterization of a novel animal model for TAF1 ID syndrome in which theTAF1gene is deleted in embryonic rats using clustered regularly interspaced short palindromic repeats (CRISPR) associated protein 9 (Cas9) technology and somatic brain transgenesis mediated by lentiviral transduction. Rat pups, post-natal day 3, were subjected to intracerebroventricular (ICV) injection of either gRNA-control or gRNA-TAF1 vectors. Rats were subjected to a battery of behavioral tests followed by histopathological analyses of brains at post-natal day 14 and day 35.TAF1-edited rats exhibited behavioral deficits at both the neonatal and juvenile stages of development. Deletion of TAF1 lead to a hypoplasia and loss of the Purkinje cells. Abnormal motor symptoms in TAF1-edited rats were associated with irregular cerebellar output caused by changes in the intrinsic activity of the Purkinje cells. Immunostaining revealed a reduction in the expression of the CaV3.1 T-type calcium channel. This animal model provides a powerful new tool for studies of neuronal dysfunction in conditions associated with TAF1 abnormalities and should prove useful for developing therapeutic strategies to treat TAF1 ID syndrome.Significance Statement: Intellectual disability (ID) syndrome is an X-linked rare disorder caused by loss-of-function mutations in theTAF1gene. There is no animal model for understanding neuronal pathology and to facilitate development of new therapeutics for this X-linked intellectual disability syndrome. Novel animal models are valuable tools for understanding neuronal pathology and to facilitate development of new therapeutics for diseases. Here we developed a novel animal model for TAF1 ID syndrome in which theTAF1gene is deleted by CRISPR-Cas9 editing and lentiviral transduction. This animal model provides a powerful new tool for studies of neuronal dysfunction associated with TAF1 abnormalities and should prove useful for developing therapeutic strategies to treat TAF1 ID syndrome.
- Open Access
- 16 July 2018
- Published by Portland Press Ltd. in Neuronal Signaling
- Vol. 2 (3) , NS20180141
A novel variant in TAF1 affects gene expression and is associated with X-linked TAF1 intellectual disability syndrome
We investigated the genome of a 5-year-old male who presented with global developmental delay (motor, cognitive, and speech), hypotonia, possibly ataxia, and cerebellar hypoplasia of unknown origin. Whole genome sequencing (WGS) and mRNA sequencing (RNA-seq) were performed on a family having an affected proband, his unaffected parents, and maternal grandfather. To explore the molecular and functional consequences of the variant, we performed cell proliferation assays, quantitative real-time PCR (qRT-PCR) array, immunoblotting, calcium imaging, and neurite outgrowth experiments in SH-SY5Y neuroblastoma cells to compare the properties of the wild-type TATA-box-binding protein factor 1 (TAF1), deletion of TAF1, and TAF1 variant p.Ser1600Gly samples. The whole genome data identified several gene variants. However, the genome sequence data failed to implicate a candidate gene as many of the variants were of unknown significance. By combining genome sequence data with transcriptomic data, a probable candidate variant, p.Ser1600Gly, emerged in TAF1. Moreover, the RNA-seq data revealed a 90:10 extremely skewed X-chromosome inactivation (XCI) in the mother. Our results showed that neuronal ion channel genes were differentially expressed between TAF1 deletion and TAF1 variant p.Ser1600Gly cells, when compared with their respective controls, and that the TAF1 variant may impair neuronal differentiation and cell proliferation. Taken together, our data suggest that this novel variant in TAF1 plays a key role in the development of a recently described X-linked syndrome, TAF1 intellectual disability syndrome, and further extends our knowledge of a potential link between TAF1 deficiency and defects in neuronal cell function.
- 16 July 2018
- Published by Portland Press Ltd. in Neuronal Signaling
- Vol. 2 (3) , NS20180141
Open AccessA novel variant in TAF1 affects gene expression and is associated with X-linked TAF1 intellectual disability syndrome
We investigated the genome of a 5-year-old male who presented with global developmental delay (motor, cognitive, and speech), hypotonia, possibly ataxia, and cerebellar hypoplasia of unknown origin. Whole genome sequencing (WGS) and mRNA sequencing (RNA-seq) were performed on a family having an affected proband, his unaffected parents, and maternal grandfather. To explore the molecular and functional consequences of the variant, we performed cell proliferation assays, quantitative real-time PCR (qRT-PCR) array, immunoblotting, calcium imaging, and neurite outgrowth experiments in SH-SY5Y neuroblastoma cells to compare the properties of the wild-type TATA-box-binding protein factor 1 (TAF1), deletion of TAF1, and TAF1 variant p.Ser1600Gly samples. The whole genome data identified several gene variants. However, the genome sequence data failed to implicate a candidate gene as many of the variants were of unknown significance. By combining genome sequence data with transcriptomic data, a probable candidate variant, p.Ser1600Gly, emerged in TAF1. Moreover, the RNA-seq data revealed a 90:10 extremely skewed X-chromosome inactivation (XCI) in the mother. Our results showed that neuronal ion channel genes were differentially expressed between TAF1 deletion and TAF1 variant p.Ser1600Gly cells, when compared with their respective controls, and that the TAF1 variant may impair neuronal differentiation and cell proliferation. Taken together, our data suggest that this novel variant in TAF1 plays a key role in the development of a recently described X-linked syndrome, TAF1 intellectual disability syndrome, and further extends our knowledge of a potential link between TAF1 deficiency and defects in neuronal cell function.
- 17 July 2015
- Published by Wiley in FEBS Letters
- Vol. 589 (18) , 2388-2393
The S100P/RAGE signaling pathway regulates expression of microRNA‐21 in colon cancer cells
S100P signaling through the receptor for advanced glycation end‐products (RAGE) contributes to colon cancer invasion and metastasis, but the mechanistic features of this process are obscure. Here, we investigate whether activation of S100P/RAGE signaling regulates oncogenic microRNA‐21 (miR‐21). We show that exogenous S100P up‐regulates miR‐21 levels in human colon cancer cells, whereas knockdown of S100P results in a decrease of miR‐21. Furthermore, blockage of RAGE with anti‐RAGE antibody suppresses S100P induction of miR‐21. In addition, we found that S100P induction of miR‐21 expression involves ERK and is suppressed by the MEK inhibitor U0126. Also, S100P treatment stimulates the enrichment of c‐Fos, and AP‐1 family members, at the miR‐21 gene promoter.
- 17 July 2015
- Published by Wiley in FEBS Letters
- Vol. 589 (18) , 2388-2393
The S100P/RAGE signaling pathway regulates expression of microRNA‐21 in colon cancer cells
S100P signaling through the receptor for advanced glycation end‐products (RAGE) contributes to colon cancer invasion and metastasis, but the mechanistic features of this process are obscure. Here, we investigate whether activation of S100P/RAGE signaling regulates oncogenic microRNA‐21 (miR‐21). We show that exogenous S100P up‐regulates miR‐21 levels in human colon cancer cells, whereas knockdown of S100P results in a decrease of miR‐21. Furthermore, blockage of RAGE with anti‐RAGE antibody suppresses S100P induction of miR‐21. In addition, we found that S100P induction of miR‐21 expression involves ERK and is suppressed by the MEK inhibitor U0126. Also, S100P treatment stimulates the enrichment of c‐Fos, and AP‐1 family members, at the miR‐21 gene promoter.
- 1 September 2013
- Published by Elsevier in Cancer Genetics
- Vol. 206 (9-10) , 309-316
How microRNAs influence both hereditary and inflammatory-mediated colon cancers
- 1 September 2013
- Published by Elsevier in Cancer Genetics
- Vol. 206 (9-10) , 309-316
How microRNAs influence both hereditary and inflammatory-mediated colon cancers
- 1 August 2013
- Published by Elsevier in Experimental Cell Research
- Vol. 319 (13) , 2081-2090
S100P/RAGE signaling regulates microRNA-155 expression via AP-1 activation in colon cancer
- 1 August 2013
- Published by Elsevier in Experimental Cell Research
- Vol. 319 (13) , 2081-2090
S100P/RAGE signaling regulates microRNA-155 expression via AP-1 activation in colon cancer